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The Role of Heart-Type Fatty Acid-Binding Protein
(H-FABP) in Acute Myocardial Infarction (AMI)
Compared to Conventional Cardiac Biochemical Markers
Aim: To investigate the clinical implications of serum heart-type fatty acid-binding protein (H-FABP) compared
to myoglobin, cardiac troponin I (cTnI), and creatine kinase MB isoenzyme (CK-MB) in patients with early
phase acute myocardial infarction (AMI).
Material and Methods: Patients were grouped clinically according to the American College of
Cardiology/European Society of Cardiology new definition of myocardial infarction (MI) and by clinician
diagnosis of MI. Serum concentrations of H-FABP, myoglobin, cTnI, and CK-MB were determined in 21
patients with AMI and 44 non-AMI patients. From each patient 3 blood samples were obtained 1-2, 3, and 6
h after the onset chest pain. The samples were compared to those of 20 age-matched healthy subjects. All the
patients and healthy subjects had normal renal function.
Results: At 1-2, 3, and 6 h after the onset of AMI, similar to myoglobin, the diagnostic sensitivity and
specificity of H-FABP were higher than those of cTnI and CK-MB. Greater receiver operating characteristic
(ROC) curve areas for the diagnosis of MI, by both sets of criteria, were obtained for H-FABP and myoglobin
compared to both cTnI and CK-MB.
Conclusion: H-FABP and myoglobin are reliable biochemical markers for superacute phase AMI and the
changes in their serum concentrations have clinical significance in the diagnosis of AMI.
Key Words: Heart-type fatty acid binding protein, acute myocardial infarction, myocardial injury

Akut Miyokard Enfarktüsünde Genel Kardiak Biyokimyasal Belirteçlerle
K›yasland›¤›nda Heart-Type Fatty Acid-Binding Protein’in Rolü
Amaç: Akut miyokard enfarktüsünün (AMI) erken faz›ndaki hastalarda serum heart-type fatty acid-binding
protein (H-FABP) ile birlikte miyoglobin, kardiak troponin I (cTn I), kreatin kinaz (CK-MB) izoenzim
seviyelerinin klinik anlam›n› araﬂt›rmak.
Yöntem ve Gereç: Hastalar klinik olarak American College of Cardiology/European Society of Cardiology
topluluklar›n›n yeni tan›m›na göre ve klinisyenlerce miyokard enfarktüsü (MI) tan›s› konularak
grupland›r›lm›ﬂt›r. 21 AMI geçiren ve 44 AMI geçirmeyen hastalarda serum H-FABP, miyoglobin, cTn I, CKMB konsantrasyonlar› ölçülmüﬂtür. Gö¤üs a¤r›s›n›n baﬂlang›c›ndan sonra, her hastadan 1-2.saat, 3. saat,
6.saatlerde 3 örnek al›nm›ﬂ ve ayn› yaﬂlarda 20 sa¤l›kl› kiﬂilerle ölçümleri karﬂ›laﬂt›r›lm›ﬂt›r. Hastalar›n ve
sa¤l›kl› grubun böbrek fonksiyonlar› normaldir.
Bulgular: AMI’›n 1-2, 3, 6.saatlerinde miyoglobin ile benzer olarak H-FABP’in tan›s›n›n duyarl›l›¤› ve
özgüllü¤ü, cTn I ve CK-MB’den daha yüksektir. MI tan›s›nda, H-FABP ve miyoglobinin ROC (receiver operating
characteristic) e¤rilerinin alanlar›, cTn I ve CK-MB’den daha büyüktür.
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Sonuç: H-FABP ve miyoglobin, AMI’›n superakut faz› için güvenilir biyokimyasal belirteçlerdir ve serum
konsantrasyonlar›ndaki de¤iﬂimler AMI’›n tan›s›nda klinik olarak önemlidir.
Anahtar Sözcükler: Heart-type fatty acid-binding protein, Akut miyokard enfarktüsü, miyokardiyal hasar
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Introduction
Acute myocardial infarction (AMI) is a common cause of sudden death. Serial
measurement of biochemical markers is now universally accepted as an important
determinant in AMI diagnosis; however, the early diagnosis of AMI is still problematic.
Therefore, a rapid method for early diagnosis of AMI is crucial (1).
The biochemical markers myoglobin, creatine kinase-MB isoenzyme (CK-MB), and
cardiac troponin I (cTnI) or troponin T (cTnT) are currently used in the diagnosis of AMI

61

PAﬁAO⁄LU, H et al.

Heart-Type Fatty Acid-Binding Protein in Acute Myocardial Infarction

(2). These cardiac marker proteins, however, are not
satisfactory for detecting AMI in the early phase,
especially within 3-6 h of the onset of AMI (3). Myoglobin
is a small protein (18 kDa), which appears in the plasma
after myocardial infarction (MI) and is considered a useful
marker for the early detection of AMI (4). Myoglobin
lacks specificity because myoglobin that is released from
skeletal muscles cannot be distinguished from that
released from the heart; therefore, it has been reported
to be less specific for myocardial damage (5).
cTnI and CK-MB are more specific for myocardial
injury, but lack early sensitivity because their blood
concentrations do not increase until 6-8 h after the onset
of AMI (6,7).
Heart-type fatty acid-binding protein (H-FABP) is a
low molecular mass, soluble protein (15 kDa), which is
abundant in the cytoplasm of myocardial cells. It
constitutes a biological marker that is quickly released
into the circulation after myocardial injury (8).
Recent data suggest that H-FABP concentration
increases well before markers of cardiac necrosis and that
it is a sensitive indicator of ischemia in AMI. Plasma HFABP increases within 3 h of AMI and returns to
reference values within 12-24 h (9). Furthermore, HFABP has been proven to be an independent factor for
prognosis in patients with a serious condition on arrival at
emergency departments (10).
In the present study, we compared the diagnostic
efficiency of the H-FABP test with cTnI, CK-MB, and
myoglobin in the early phase (1-2, 3, and 6 h) of AMI. We
sought to determine if H- FABP levels during early stage
AMI (1-2 h) have high sensitivity and specificity for AMI
diagnosis, which if they did would contribute greatly to
clinical practice and reduce useless emergency
examinations to a minimum.

Material and Methods
Blood samples were collected with the approval of the
local ethics committee of Gazi University Faculty of
Medicine. Blood samples are obtained from 65 patients,
who were admitted within 1-2 h of the onset of chest
pain (21 AMI and 44 non-AMI) to the coronary
emergency department. Mean age of the patients was
58.2 ± 12 years. After the start of chest pain, most
patients delay calling for emergency medical help. Thus, it
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takes nearly 4-5 h to get to coronary emergency
departments, and we excluded such patients from our
study. The study included 20 age-matched healthy
controls (mean age: 57.1 ± 10 years). Patients and
controls had normal renal function and no muscle trauma.
Chest pain patients who did not have AMI (non-AMI) were
diagnosed with unstable angina, stable angina, or other
cardiovascular diseases. Blood samples were collected
from each patient at 1-2, 3, and 6 h after the onset of
chest pain. Samples from 20 healthy controls were
assayed for all cardiac markers. Blood samples were
centrifuged, serum was separated, and all were stored at
–80 ºC until assayed.
H-FABP was assayed using a solid-phase enzymelinked immunosorbent assay (ELISA) based on the
sandwich principle (Life Diagnostics, Inc, ELISA Test Kit,
2310). Myoglobin, cTnI, and CK-MB tests were assayed
using ELISA test kits (DRG Instruments GmbH, Germany,
EIA-3955, myoglobin, EIA-2952 cTnI, EIA-4112, CKMB). The recommended reference range for H-FABP is
1.6-19 ng/ml (cut-off for AMI: > 19). For myoglobin,
cTnI, and CK-MB, the reference ranges were 8.1-54.5
ng/ml, 0-1.5 ng/ml, and 2-5.2 ng/ml, respectively.
Diagnostic Definition of AMI
Diagnoses were classified into 2 groups: AMI and nonAMI chest pain. AMI was defined according to the
European Society of Cardiology/American College of
Cardiology Committee criteria (11).
Either one of the following criteria satisfies the
diagnosis for an acute, evolving, or recent MI: 1) Typical
rise and gradual fall (troponin), or more rapid rise and fall
(CK-MB) of biochemical markers of myocardial necrosis,
with at least one of the following: a) ischemic symptoms;
b) development of pathologic Q waves on ECG; c) ECG
changes indicative of ischemia (ST segment elevation or
depression); or d) coronary artery intervention (e.g.,
coronary angioplasty); 2) Pathologic findings of an acute
MI. Criteria for established MI. Any one of the following
criteria satisfies the diagnosis for established MI:
1) Development of new pathologic Q waves on serial
ECGs. The patient may or may not remember previous
symptoms. Biochemical markers of myocardial necrosis
may have normalized, depending on the length of time
that has passed since the infarct developed.
2) Pathologic findings of a healed or healing MI.
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The data from ROC analysis are summarized in Figure
1; areas under the ROC curves and P values are
summarized in Table 4. In the areas under the ROC
curves H-FABP and myoglobin in the AMI group were
significantly higher (P = 0.00) than in the non-AMI group
at 1-2, 3, and 6 h. cTnI in the AMI group was significantly
higher (P = 0.00) than in the non-AMI group at 3 and 6
h, and CK-MB in the AMI group was significantly higher
(P = 0.00) than in the non-AMI group at 6 h (Table 4)

Samples were grouped according to designated timeframes for onset of symptoms within 1-2, 3, and 6 h.
The diagnostic value of tests was evaluated by the
sensitivity, specificity, and receiver operating
characteristic (ROC) curves. The 95% confidence
intervals were calculated. Differences in sensitivity and
specificity were evaluated by ROC curve. Results are given
as mean ± SD, P values, and cut-off values according to
sample times (asymptotic 95% confidence interval). P
values < 0.05 were considered statistically significant.

The sensitivity and specificity of the cut-off values for
H-FABP, myoglobin, cTnI, and CK-MB are shown in Table
5.

Results
Discussion

There were 21 patients in the AMI group, 44 patients
in the non-AMI group, and 20 healthy participants in the
control group. Serum concentrations of H-FABP,
myoglobin, cTnI, and CK-MB are given as mean ± SD in
Tables 1-3. In blood samples collected at 1-2 and 3 h, HFABP and myoglobin in the AMI group were significantly
higher (P = 0.00) than in the non-AMI and control
groups. cTnI and CK-MB in the AMI group were not yet
significantly higher than in non-AMI and control groups at
1-2 h. cTnI in the AMI group was higher than in the nonAMI and control groups at 3 h. CK-MB in the AMI group
was higher than in the control group, but not in the nonAMI group at 3 h. All parameters in the AMI group were
significantly higher than in the non-AMI and control
groups at 6 h (Tables 1-3).

The principal characteristics that would make a
marker of myocardial damage ideal for the early clinical
diagnosis of AMI by analyzing its plasma concentration
include: (1) small size; a small-size molecular marker is
more rapidly released into the circulation, allowing early
identification of myocardial damage; (2) absence or
presence only in trace amounts in the circulation under
physiological conditions, because this implies a very
narrow reference range; thus, detection as abnormal with
even minimal increases of the marker in plasma is
possible; (3) absolute specificity for the myocardium,
since most proteins in the heart also are abundant in
skeletal muscle, especially under pathological conditions
(12). Wu et al. (13) recommended that 2 biochemical

Table 1. Results are given as mean ± SD for 1-2 h after symptom onset.
H-FABP (1-2 h)

Myoglobin (1-2 h)

Population

Mean ± SD

P

Control
n = 20

9.33 ± 3.9

0.00

AMI
n = 21

70.38 ± 41.35

0.00

11.51 ± 3.8

0.040

Non-AMI
n = 44

cTnI (1-2 h)

Mean ± SD

P

a

10.42 ± 4.63

0.00

b

61.50 ± 46.48

0.00

13.40 ± 5.15

0.016

c

CK-MB (1-2 h)

Mean ± SD

P

a

0.42 ± 0.50

0.232
(NS)

b

0.55 ± 0.47

0.882
(NS)

0.52 ± 0.40

c

Mean ± SD

P

a

1.52 ± 0.56

0.771
(NS)

a

b

1.58 ± 0.92

0.499
(NS)

b

0.082 c
(NS)

1.82 ± 1.24

0.695
(NS)

c

NS: not significant
P value < 0.05 was considered statistically significant.
a

control vs. AMI
AMI vs. non-AMI
c
Non-AMI vs. control
b
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Table 2. Results are given as mean ± SD for 3 h after symptom onset.
H-FABP (3h)

Myoglobin (3h)

cTnI (3h)

CK-MB (3h)

Population
Mean ± SD

P

Mean ± SD

P

Control
n = 20

9.33 ± 3.9

0.00

AMI
n = 21

83.42 ± 40.90

0.00

Non-AMI
n = 44

11.20 ± 3.35

0.047

a

10.42 ± 4.63

0.00

b

83.69 ± 49.83

0.00

12.91 ± 5.03

0.045

c

Mean ± SD

P

a

0.42 ± 0.50

0.007

b

0.95 ± 0.69

0.45 ± 0.36

c

Mean ± SD

P

a

1.52 ± 0.56

0.009

0.009

b

2.79 ± 1.70

0.072 b
(NS)

0.100
(NS)

c

2.03 ± 1.28

0.217 c
(NS)

a

NS: not significant
P value < 0.05 was considered statistically significant.
a

control vs. AMI
AMI vs. non-AMI
c
Non-AMI vs. control
b

Table 3. Results are given as mean ± SD for 6 h after symptom onset.
H-FABP (6h)

Myoglobin (6h)

cTnI (6h)

CK-MB (6h)

Population
Mean ± SD

P

Mean ± SD

P

Control
n = 20

9.33 ± 3.9

0.00

AMI
n = 21

99.33 ± 41.8

0.00

Non-AMI
n = 44

11.31 ±3.32

0.039

a

10.42 ± 4.63

0.00

b

109.50 ± 47.08

0.00

14.13 ± 5.88

0.013

c

Mean ± SD

P

a

0.42 ± 0.50

0.00

b

2.17 ± 1.89

0.00

0.50 ± 0.40

0.043

c

Mean ± SD

P

a

1.52 ± 0.56

0.00

a

b

4.40 ± 2.16

0.00

b

2.16 ± 1.37

0.110
(NS)

c

c

NS: not significant.
P value < 0.05 was considered statistically significant.
a

Control vs. AMI
AMI vs. non-AMI
c
Non-AMI vs. control
b

markers should be used for routine AMI diagnosis; an
early marker (reliably increased in blood within 6 h of the
onset of symptoms) and a definitive marker (increased in
blood after 6-9 h, with high sensitivity and specificity for
myocardial injury, and remaining abnormal for several
days after onset). A recent substantial increase in the use
of cTnI or cTnT, CK-MB mass, and myoglobin assays for
the detection of MI has been observed (14). Collinson et
al. (15) showed that measurement of cTnT was
diagnostically equivalent to CK-MB and that both were
better than myoglobin 12 h after symptom onset. CK-MB
is unsuitable as a diagnostic gold standard, even at the
64

proposed lower threshold. Diagnosis of AMI cannot be
made solely on the basis of a cardiac troponin T result.
Yamamoto et al. (16) demonstrated that a rapid,
quantitative test for cTnT and myoglobin is useful for
early diagnosis of AMI and as an indicator of its severity
at 6, 12, 24, 48 h after onset of MI. To date, myoglobin
has been used as a biochemical cardiac marker for the
diagnosis of AMI in the hyperacute phase, that is, within
3 h after the onset of symptoms. However, myoglobin is
not very specific for myocardial damage because of its
abundance in skeletal muscle as well as the myocardium
(12). H-FABP is released rapidly from the myocardium
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into the bloodstream after ischemic injury (17). Since HFABP is a smaller molecule than myoglobin, cTnI, and CKMB, it peaks earlier than these other molecules when
there is cardiomyocyte damage.
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.5
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1.0

A-C. ROC plots of the AMI group versus the non-AMI group,
according to sample times (1-2, 3 and 6 h after symptom
onset).
A. ROC plot of the AMI group versus the non-AMI group 12 h after symptom onset.
B. ROC plot of the AMI group versus the non-AMI group 3
h after symptom onset.
C. ROC plot of the AMI group versus the non-AMI group 6
h after symptom onset.

We have demonstrated the sensitivity and specificity
of H-FABP for the detection of early phase AMI, and
compared it to the routinely used markers, myoglobin,
cTnI, and CK-MB. The present data indicates that for AMI
detection, serum H-FABP shows a significantly higher
diagnostic sensitivity and specificity than cTnI and CK-MB,
similar to myoglobin, especially soon after (within 1-2
and at 3 h) the onset of symptoms.
The diagnostic sensitivity of H-FABP has been
suggested to be high, greater than that of myoglobin in
patients presenting within 6 h of the onset of chest pain
(18). This superiority could be attributed to an earlier and
more rapid rise in H-FABP than in myoglobin. After
thrombolysis, serum concentrations of H-FABP peak
approximately 4 h after the onset of chest pain and
return to normal values within 24 h. Because of its rapid
return to baseline, H-FABP can contribute as an early
biological marker of post thrombolysis (19,20). In
addition, when compared to myoglobin, H-FABP
concentration in the heart muscle is greater than that in
skeletal muscle, and its normal baseline concentration is
several-fold lower than myoglobin. These advantages
make H-FABP a potentially more suitable cardiac marker
than myoglobin (21).
In contrast, Alansari and Croal (22) suggested that HFABP and myoglobin provide little clinical value,
compared to cTnI, when measured at presentation in
patients presenting with chest pain (3-12 h). Xiano et al.
(23) investigated the clinical implication of cTnI,
myoglobin, and CK-MB in patients with AMI 2-4 h after
chest pain onset and showed that cTnI and myoglobin are
reliable biochemical markers for early diagnosis of MI.
Consequently, Ishii et al. (24) suggested that H-FABP
concentrations have a greater predictive capacity for
cardiac events than cardiac troponin within 6 h of the
onset of chest pain. Conflicting results about cardiac
markers may be explained by the duration of MI at the
time of sampling or other factors in MI studies. In our
study, cTnI of the AMI group was higher than in the nonAMI and control groups at 3 h, but at not 1-2 h. This
result showed that H-FABP and myoglobin are more
sensitive than cTnI and CK-MB in the detection of
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Table 4. Areas under ROC curves and P values according to sample times (asymptotic 95% confidence interval).

H-FABP
Population

Time
(hours)

AMI + NonAMI

1-2

ROC

95% CI

Myoglobin
P

ROC

cTnI

95% CI

P

ROC

CK-MB

95% CI

P

ROC

%95 CI

p

0.983 0.957-1.008

0.00

0.999 0.997-1.002

0.00

0.489

0.330-0.647 0.883

0.449 0.298-0.600 0.505

3

1.00

1.00-1.00

0.00

1.00

1.00-1.00

0.00

0.701

0.548-0.854 0.009

0.638 0.492-0.784 0.074

6

1.00

1.00-1.00

0.00

1.00

1.00-1.00

0.00

0.883

0.786-0.980 0.00

0.822 0.718-0.926 0.00

Table 5. The effect on sensitivity and specificity of the cut-off values for H-FABP, myoglobin, cTnI, and CK-MB in the AMI versus non-AMI groups.
Markers

1-2 h

sensitivity

specificity

3h

sensitivity

specificity

6h

sensitivity

specificity

HFABP (ng/ml)

19.5

0.90

0.95

18.50

1.0

0.97

19.50

1.0

0.97

Myoglobin (ng/ml)

21.75

1.00

0.89

24.50

1.0

1.0

44.25

1.0

1.0

cTnI (ng/ml)

0.25

0.57

0.36

0.55

0.66

0.70

1.35

0.71

0.97

CK-MB (ng/ml)

1.05

0.42

0.31

1.75

0.71

0.50

2.20

0.85

0.72

myocardial injury, especially within 1-2 h of symptom
onset. Moreover, ROC curve areas for H-FABP and
myoglobin were better than those of cTnI and CK-MB <
6 h after the onset of chest pain.
The combined measurement of serum H-FABP and
myoglobin in the superacute phase (within 3 h) allows the
discrimination between myocardial and skeletal muscle
injury. The late markers cTnI and CPK showed similar
diagnostic performance 6 h after symptom onset. Thus,
late measurement of H-FABP allows the earliest
immunochemical confirmation or exclusion of AMI (25).
Furthermore, some studies showed that H-FABP is a
useful biochemical plasma marker for the estimation of
myocardial infarct size in humans and mice, which might
be helpful in clinically anticipating infarction prognosis
(26,27). Moreover, plasma H-FABP concentration can
help in the postmortem diagnosis of AMI in rats (12).

In conclusion, H-FABP is a sensitive and specific
marker for the early diagnosis of AMI. The H-FABP assay
was suggested to effectively exclude non-AMI patients
within 3 h of the onset of chest pain. For the use of HFABP as an early marker in the detection of myocardial
injury, the assay must have a fast turn-around time.
Several biochemical assays of H-FABP have been
described; however, the use of these assays in routine
clinical practice is limited because of the fact that they are
not automated. The clinical application of H-FABP
requires the availability of rapid assay kits in routine
automatic systems at emergency departments.
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